Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

20.65 -0.15 (-0.72%)
Streaming Delayed Price Updated: 2:28 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Innoviva, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
News headline image
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
From Innoviva Specialty Therapeutics, Inc.
Via Business Wire
News headline image
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the UBS Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in Upcoming Investor Conferences
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the BofA Securities Health Care Conference
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
Innoviva to Participate in the Cantor Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
From Innoviva, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.